Bukwang Pharmaceutical (003000) Fundamentals 2026 — P/E 26.7x, Revenue Analysis | SniperIQ
Bukwang Pharmaceutical (003000) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩369.0B, trading at ₩3740.00 on the KSC. This SniperIQ fundamentals page covers Bukwang Pharmaceutical's valuation (P/E 26.7x, P/B 1.1x), profitability (net margin 6.9%), revenue (₩200.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bukwang Pharmaceutical's market cap?
Bukwang Pharmaceutical (003000) has a market capitalization of approximately ₩369.0B, trading at ₩3740.00 on the KSC. Market cap moves with the live share price.
What is Bukwang Pharmaceutical's P/E ratio?
Bukwang Pharmaceutical's trailing twelve-month P/E ratio is 26.7x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bukwang Pharmaceutical?
Bukwang Pharmaceutical runs a net profit margin of 6.9%, a gross margin of 45.8%, and an operating margin of 6.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bukwang Pharmaceutical generate?
Bukwang Pharmaceutical reported revenue of ₩200.7B for fiscal year 2025, with net income of ₩12.6B and earnings per share (EPS) of 152. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bukwang Pharmaceutical pay a dividend?
Bukwang Pharmaceutical offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bukwang Pharmaceutical financially healthy?
Bukwang Pharmaceutical carries a debt-to-equity ratio of 0.24x and a current ratio of 2.55x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bukwang Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bukwang Pharmaceutical (003000) the key facts are: market cap ₩369.0B, P/E 26.7x, revenue ₩200.7B, 52-week range 3200-9890. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bukwang Pharmaceutical's full fundamentals live
Get Bukwang Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.